Topical treatment of onychomycosis with efinaconazole solution 10%

Cutis

Volumn 91, Issue 6, 2013, Pages 305-307

  Rich, Phoebe ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; EFINACONAZOLE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; HUMAN; MALE; MICROBIOLOGY; ONYCHOMYCOSIS; SKIN DISEASE; TRICHOPHYTON;

ADULT; ANTIFUNGAL AGENTS; FOOT DERMATOSES; HUMANS; MALE; ONYCHOMYCOSIS; TRIAZOLES; TRICHOPHYTON;

EID: 84882257015     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Scher RK, Coppa LM. Advances in the diagnosis and treatment of onychomycosis. Hosp Med. 1998;34:11-20.
2. Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol. 2000;43(2, pt 1):244-248.
3. Roberts DT. Onychomycosis: current treatment and future challenges. Br J Dermatol. 1999;141(suppl 56):1-4.
4. Kumar S, Kimball AB. New antifungal therapies for the treatment of onychomycosis. Expert Opin Investig Drugs. 2009;18:727-734.
5. Drake LA, Patrick DL, Fleckman P, et al. The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol. 1999;41(2, pt 1):189-196.
6. Scher RK. Onychomycosis: a significant medical disorder. J Am Acad Dermatol. 1996;35(3, pt 2):S2-S5.
7. Lubeck DP, Patrick DL, McNulty P, et al. Quality of life of persons with onychomycosis. Qual Life Res. 1993;2:341-348.
8. Whittam LR, Hay RJ. The impact of onychomycosis on quality of life. Clin Exp Dermatol. 1997;22:87-89.
9. Reich A, Szepietowski JC. Health-related quality of life in patients with nail disorders. Am J Clin Dermatol. 2011;12:313-320.
10. Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies [published online ahead of print November 22, 2012]. J Am Acad Dermatol. 2013;68:600-608.
11. Baran R, Sigurgeirsson B, de Berker D, et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement [published online ahead of print June 6, 2007]. Br J Dermatol. 2007;157:149-157.
12. Fungal nail infections: diagnosis and management. Prescrire Int. 2009;18:26-30.
13. Piraccini BM, Sisti A, Tosti A. Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol. 2010;62:411-414.
14. Sparavigna A, Setaro M, Frisenda L. Physical and microbiological properties of a new nail protective medical device. J Plastic Dermatol. 2008;4:5-12.
15. Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol. 2005;19:21-29.
16. Lecha M, Effendy I, Feuilhade de Chauvin M, et al. Treatment options-development of consensus guidelines. J Eur Acad Dermatol Venereol. 2005;19(suppl 1):25-33.
17. Murdan S. Drug delivery to the nail following topical application [published correction in Int J Pharm. 2010;392:314]. Int J Pharm. 2002;236:1-26.
18. Newland JG, Abdel-Rahman SM. Update on terbinafine with a focus on dermatophytoses. Clin Cosmet Investig Dermatol. 2009;2:49-63.
19. De Cuyper C, Hindryckx PH. Long-term outcomes in the treatment of toenail onychomycosis. Br J Dermatol. 1999;141(suppl 56):15-20.
20. Werschler WP, Bondar G, Armstrong D. Assessing treatment outcomes in toenail onychomycosis clinical trials. Am J Clin Dermatol. 2004;5:145-152.
21. Elewski BE, Ghannoum MA, Mayser P, et al. Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs [published online ahead of print December 20, 2011]. J Eur Acad Dermatol Venereol. doi:10.1111/j.1468-3083.2011.04373.x.